Reduced expression of miR-503 is associated with poor prognosis in cervical cancer

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 21, 2015, Pages 4081-4085

  Yin, Z L ^a   Wang, Y L ^b   Ge, S F ^a   Guo, T T ^a   Wang, L ^a   Zheng, X M ^a   Liu, J ^a  

^a LINYI PEOPLE'S HOSPITAL   (China)

^b People's Procuratorate of Lanshan District   (China)

Author keywords

Cervical cancer; MicroRNA 503; Overall survival; QPCR; Recurrence free survival

Indexed keywords

MICRORNA; MICRORNA 503; UNCLASSIFIED DRUG; MIRN503 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM; AGED; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

AGED; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 84958159442     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. JEMAL A, BRAY F, CENTER MM, FERLAY J, WARD E, FORMAN D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. BRAY F, REN JS, MASUYER E, FERLAY J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132: 1133-1145.
3. ARBYN M, CASTELLSAGUE X, DE SANJOSE S, BRUNI L, SARAIYA M, BRAY F, FERLAY J. WORLDWIDE BURDEN OF cervical cancer in 2008. Ann Oncol 2011; 22: 2675-2686.
4. TAO X, HU W, RAMIREZ PT, KAVANAGH JJ. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 2008; 110: S67-71.
5. BARTEL DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
6. HE L, HANNON GJ. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
7. BAEK D, VILLEN J, SHIN C, CAMARGO FD, GYGI SP, BARTEL DP. The impact of microRNAs on protein output. Nature 2008; 455: 64-71.
8. TAY Y, RINN J, PANDOLFI PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505: 344-352.
9. HU Y, TANG H. MicroRNAs regulate the epithelial to mesenchymal transition (EMT) in cancer progression. Microrna 2014; 3: 108-117.
10. CHEN CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768-1771.
11. LU J, GETZ G, MISKA EA, ALVAREZ-SAAVEDRA E, LAMB J, PECK D, SWEET-CORDERO A, EBERT BL, MAK RH, FERRANDO AA, DOWNING JR, JACKS T, HORVITZ HR, GOLUB TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
12. ZHANG B, PAN X, COBB GP, ANDERSON TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
13. LU YC, CHEN YJ, WANG HM, TSAI CY, CHEN WH, HUANG YC, FAN KH, TSAI CN, HUANG SF, KANG CJ, CHANG JT, CHENG AJ. Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res (Phila) 2012; 5: 665-674.
14. Zhou J, Wang W. Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg Oncol 2011; 104: 278-283.
15. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A, Zedenius J, Backdahl M, Larsson C, Lui WO. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011; 18: 643-655.
16. ZHAO JJ, YANG J, LIN J, YAO N, ZHU Y, ZHENG J, XU J, CHENG JQ, LIN JY, MA X. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 2009; 25: 13-20.
17. CORBETTA S, VAIRA V, GUARNIERI V, SCILLITANI A, ELLERVAINICHER C, FERRERO S, VICENTINI L, CHIODINI I, BISCEGLIA M, BECK-PECCOZ P, BOSARI S, SPADA A. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer 2010; 17: 135-146.
18. COLOMBO N, CARINELLI S, COLOMBO A, MARINI C, ROLLO D, SESSA C. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7: Vii27-32.
19. ESTELLER M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874.
20. KIM M, KASINSKI AL, SLACK FJ. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol 2011; 12: 319-321.
21. BROWN JR, SANSEAU P. A computational view of microRNAs and their targets. Drug Discov Today 2005; 10: 595-601.
22. SU YH, ZHOU Z, YANG KP, WANG XG, ZHU Y, FA XE. MIR-142-5p and miR-9 may be involved in squamous lung cancer by regulating cell cycle related genes. Eur Rev Med Pharmacol Sci 2013; 17: 3213-3220.
23. BAO JL, LIN L. MiR-155 and miR-148a reduce cardiac injury by inhibiting NF-kappaB pathway during acute viral myocarditis. Eur Rev Med Pharmacol Sci 2014; 18: 2349-2356.